Previous Study: TRIO039
Next Study: TRIO033

Studies & Results

TRIO035

A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors (MT-5111-001)

View FDA Study

Presentations

SABCS 2019

A Novel HER2-Targeting Engineered Toxin Body Under Clinical Development to Overcome Mechanisms of Resistance to Existing HER2-Targeted Therapies

ASCO GI 2021

Van Tine BA, et al.

A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in patients with HER2-positive tumors.

AACR 2021

Wainberg ZA, et al.

Phase 1 study of the novel immunotoxin MT-5111 in patients (pts) with HER-2+tumors

SABCS 2021

Van Tine BA, et al.

Interim Results of a Phase 1 study of the novel immunotoxin MT-5111 in patients with HER-2+tumors

ASCO GI 2022

Hubbard JM, Van Tine BA, et al.

A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors: Interim results.

ASCO 2022

Hubbard JM, et al.

A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: Interim results.

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org